Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera
Open Access
- 3 November 2011
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 29 (47), 8585-8590
- https://doi.org/10.1016/j.vaccine.2011.09.021
Abstract
No abstract availableFunding Information
- UK Medical Research Council (G0701217)
This publication has 35 references indexed in Scilit:
- HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protectionVaccine, 2011
- Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendmentsVirology, 2010
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenThe Lancet, 2009
- Immunogenicity Testing in Human Papillomavirus Virus‐Like‐Particle Vaccine TrialsThe Journal of Infectious Diseases, 2009
- Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus VaccinesJNCI Journal of the National Cancer Institute, 2009
- A review of human carcinogens—Part B: biological agentsPublished by Elsevier BV ,2009
- Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa RicaVaccine, 2008
- Vaccines: Correlates of Vaccine‐Induced ImmunityClinical Infectious Diseases, 2008
- Prevalence of human papillomavirus antibodies in young female subjects in EnglandBritish Journal of Cancer, 2007
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerThe New England Journal of Medicine, 2003